- Home
- RDWR vs PCRX Comparison
RDWR vs PCRX Comparison
Compare RDWR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- PCRX
- Stock Information
- Founded
- RDWR 1996
- PCRX 2006
- Country
- RDWR Israel
- PCRX United States
- Employees
- RDWR N/A
- PCRX N/A
- Industry
- RDWR EDP Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- PCRX Health Care
- Exchange
- RDWR Nasdaq
- PCRX Nasdaq
- Market Cap
- RDWR 1.0B
- PCRX 1.2B
- IPO Year
- RDWR 1999
- PCRX 2011
- Fundamental
- Price
- RDWR $27.64
- PCRX $24.32
- Analyst Decision
- RDWR Hold
- PCRX Buy
- Analyst Count
- RDWR 4
- PCRX 9
- Target Price
- RDWR $27.00
- PCRX $29.89
- AVG Volume (30 Days)
- RDWR 141.3K
- PCRX 670.5K
- Earning Date
- RDWR 07-30-2025
- PCRX 07-29-2025
- Dividend Yield
- RDWR N/A
- PCRX N/A
- EPS Growth
- RDWR N/A
- PCRX N/A
- EPS
- RDWR 0.27
- PCRX N/A
- Revenue
- RDWR $281,874,000.00
- PCRX $702,772,000.00
- Revenue This Year
- RDWR $10.38
- PCRX $7.82
- Revenue Next Year
- RDWR $7.14
- PCRX $10.56
- P/E Ratio
- RDWR $99.61
- PCRX N/A
- Revenue Growth
- RDWR 9.54
- PCRX 3.08
- 52 Week Low
- RDWR $17.01
- PCRX $11.16
- 52 Week High
- RDWR $27.11
- PCRX $29.61
- Technical
- Relative Strength Index (RSI)
- RDWR 80.67
- PCRX 38.22
- Support Level
- RDWR $23.94
- PCRX $23.50
- Resistance Level
- RDWR $24.78
- PCRX $24.75
- Average True Range (ATR)
- RDWR 0.69
- PCRX 0.87
- MACD
- RDWR 0.29
- PCRX -0.26
- Stochastic Oscillator
- RDWR 96.27
- PCRX 16.96
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. It generates the majority of its revenue from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.